ICON Public Limited (NASDAQ:ICLR) Receives Consensus Rating of “Buy” from Analysts

ICON Public Limited (NASDAQ:ICLR) has earned an average recommendation of “Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12-month price objective among analysts that have covered the stock in the last year is $269.22.

Several brokerages have recently weighed in on ICLR. StockNews.com assumed coverage on shares of ICON Public in a report on Thursday, August 17th. They set a “hold” rating on the stock. TD Cowen began coverage on ICON Public in a research note on Wednesday. They set an “outperform” rating and a $306.00 price target for the company. Deutsche Bank Aktiengesellschaft increased their target price on shares of ICON Public from $280.00 to $300.00 in a research report on Friday, July 14th. Mizuho reiterated a “buy” rating and issued a $274.00 price target on shares of ICON Public in a report on Wednesday. Finally, Barclays increased their target price on ICON Public from $250.00 to $280.00 and gave the company an “overweight” rating in a research note on Friday, July 28th.

ICON Public Trading Down 1.3 %

Shares of ICLR stock opened at $261.78 on Friday. ICON Public has a twelve month low of $171.43 and a twelve month high of $268.07. The company has a market capitalization of $21.51 billion, a price-to-earnings ratio of 42.43, a PEG ratio of 1.48 and a beta of 1.12. The firm has a 50-day moving average price of $252.56 and a 200 day moving average price of $227.95. The company has a current ratio of 1.22, a quick ratio of 1.22 and a debt-to-equity ratio of 0.48.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, July 26th. The medical research company reported $2.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.92 by $0.04. ICON Public had a net margin of 6.45% and a return on equity of 11.21%. The firm had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.02 billion. Research analysts forecast that ICON Public will post 12.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ICON Public

A number of hedge funds have recently modified their holdings of ICLR. CIBC Private Wealth Group LLC boosted its position in shares of ICON Public by 40.6% in the 1st quarter. CIBC Private Wealth Group LLC now owns 545,799 shares of the medical research company’s stock valued at $120,147,000 after purchasing an additional 157,527 shares during the period. TimesSquare Capital Management LLC increased its position in shares of ICON Public by 6.4% in the second quarter. TimesSquare Capital Management LLC now owns 220,890 shares of the medical research company’s stock worth $55,267,000 after acquiring an additional 13,335 shares in the last quarter. Todd Asset Management LLC raised its holdings in shares of ICON Public by 1.2% during the first quarter. Todd Asset Management LLC now owns 141,105 shares of the medical research company’s stock valued at $30,139,000 after acquiring an additional 1,621 shares during the period. State of Tennessee Treasury Department lifted its position in shares of ICON Public by 2.4% in the 2nd quarter. State of Tennessee Treasury Department now owns 110,747 shares of the medical research company’s stock valued at $27,709,000 after acquiring an additional 2,605 shares in the last quarter. Finally, Globeflex Capital L P boosted its stake in ICON Public by 0.8% in the 1st quarter. Globeflex Capital L P now owns 53,006 shares of the medical research company’s stock worth $11,322,000 after purchasing an additional 400 shares during the period. 95.21% of the stock is currently owned by institutional investors and hedge funds.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.